Recent Advances in Soft Tissue Tumor Pathology: Evolving Classification, Novel Molecular Findings and New Diagnostic Markers

COURSE DESCRIPTION

The diagnosis of soft tissue tumors can be a significant challenge (even for experienced pathologists) because of their rarity, the broad morphological spectrum of mesenchymal tumors, and overlap with other soft tissue tumors and non-mesenchymal neoplasms. The classification of soft tissue tumors continues to evolve, following the description of “new” tumor types, the discovery of novel molecular genetic alterations, and the development of increasingly specific diagnostic immunohistochemical markers. If your specialty interest is in soft tissue pathology, or if your practice requires enhanced competency in evaluating soft tissue lesions, this course is designed to familiarize you with recently-described soft tissue tumors and recently-developed diagnostic markers.

COURSE OBJECTIVES

•  Develop a differential diagnosis for soft tissue tumors
based on dominant histologic patterns and anatomic sites
•  Apply immunohistochemistry to help resolve the differential diagnosis
•  Understand the role of molecular genetic testing for the diagnosis of soft tissue tumors

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuing Certification.

Physicians can earn a maximum of 15 SAM credit hours.